Related Experiment Video
Updated: Mar 24, 2026
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
MLKL inhibition attenuates hypoxia-ischemia induced neuronal damage in developing brain
1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China; Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu 610041, China.
Abstract:
Mixed lineage kinase domain-like protein (MLKL) is a critical molecule mediating cell necroptosis. However, its role in brain injury remains obscure. We first investigated the functions and mechanisms of MLKL in mediating neuronal damage in developing brain after hypoxia-ischemia. Neuronal necroptosis was induced by oxygen-glucose deprivation (OGD) plus caspase inhibitor zVAD treatment (OGD/zVAD). We found that two important necroptosis related proteins, receptor-interacting protein 1 and 3 (RIP1, RIP3) were upregulated. Furthermore, the interaction of RIP1-RIP3 with MLKL increased. Inhibition of MLKL through siRNA diminished RIP1-RIP3-MLKL interaction and attenuated neuronal death induced by OGD/zVAD. The translocation of oligomerized MLKL to the neuronal membrane leading to the injury of cellular membrane is the possible new mechanism of neuronal necroptosis. Animal experiment with neonatal rats further proved that MLKL inhibition attenuated brain damage induced by hypoxia-ischemia. These findings suggest that MLKL is a target to attenuate brain damage in developing brain.
Insights
Mixed lineage kinase domain-like protein (MLKL) mediates necroptosis. Inhibiting MLKL reduces neuronal death and brain damage after hypoxia-ischemia, suggesting MLKL as a therapeutic target.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Mixed lineage kinase domain-like protein (MLKL) is a key mediator of necroptosis.
- The specific role of MLKL in developing brain injury is not well understood.
Purpose of the Study:
- To investigate the function and mechanism of MLKL in neuronal damage following hypoxia-ischemia.
- To explore MLKL as a potential therapeutic target for brain injury.
Main Methods:
- Neuronal necroptosis induced via oxygen-glucose deprivation (OGD) plus zVAD.
- Investigated MLKL, RIP1, and RIP3 protein interactions using siRNA.
- Conducted animal experiments on neonatal rats subjected to hypoxia-ischemia.
Main Results:
- Receptor-interacting protein 1 and 3 (RIP1, RIP3) were upregulated post-OGD/zVAD.
- Increased interaction between RIP1-RIP3 and MLKL was observed.
- MLKL inhibition via siRNA reduced RIP1-RIP3-MLKL interaction and neuronal death.
- Oligomerized MLKL translocation to the neuronal membrane was identified as a mechanism of injury.
- MLKL inhibition attenuated hypoxia-ischemia-induced brain damage in neonatal rats.
Conclusions:
- MLKL plays a critical role in mediating neuronal necroptosis and brain damage after hypoxia-ischemia.
- Targeting MLKL offers a promising therapeutic strategy to mitigate brain injury in developing brains.
